bioAffinity Technologies, Inc. (BIAF) Price & Analysis

Compare

135 Followers

BIAF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.40 - $67.11

Previous CloseN/A

Volume17.91K

Average Volume (3M)3.66M

Market Cap

$7.08M

Enterprise Value$6.77M

Total Cash (Recent Filing)$802.84K

Total Debt (Recent Filing)$670.00K

Price to Earnings (P/E)―

Beta-2.69

Next Earnings

Nov 12, 2025

EPS Estimate

-2.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.10

Shares Outstanding1,338,029

10 Day Avg. Volume10,856,612

30 Day Avg. Volume3,656,468

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.24

Price to Sales (P/S)1.18

P/FCF Ratio-1.50

Enterprise Value/Market Cap0.96

Enterprise Value/Revenue0.88

Enterprise Value/Gross Profit2.95

Enterprise Value/Ebitda-0.61

Forecast

1Y Price Target

$0.50

Price Target Upside-90.55% Downside

Rating ConsensusModerate Sell

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Commercial StrategyCyPath testing was up year-over-year with record testing volume in both June and July 2025, reflecting an accelerated commercialization strategy and increased clinical adoption.

Market ExpansionThe company is selling tests in several other states through referrals and word-of-mouth even before a broader commercial rollout.

Bears Say

Capital ConstraintsThe company's capital constraints remain a concern; therefore, analysts maintain a Hold rating as they believe the risk/reward is balanced.

Financial OutlookAnalysts are lowering their 2025 and 2026 revenue estimates, and widening their 2025 and 2026 GAAP loss per share estimates.

Profitability ConcernsThe inability to operate profitably and the need to raise additional capital gives analysts pause, leading to a recommendation not to purchase shares at this time.

bioAffinity Technologies, Inc. News

BioAffinity prices 1.92M common share offering at $2.50 per share

bioAffinity Technologies (BIAF) announced that it has priced a public offering of securities for aggregate gross proceeds to...

6h ago

BIAF

bioAffinity Technologies Inc trading resumes

10:47 EDT bioAffinity Technologies (BIAF) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

11h ago

BIAF

bioAffinity Technologies Inc trading halted, volatility trading pause

10:42 EDT bioAffinity Technologies (BIAF) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

11h ago

BIAF

BioAffinity Technologies files to sell 729,927 shares of common stock

Also files to sell common stock purchase warrants to purchase up to 1,094,891 shares of common stock. WallachBeth...

6d ago

BIAF

bioAffinity Technologies Inc trading halted, news pending

19:50 EDT bioAffinity Technologies (BIAF) Inc trading halted, news pending Published first on TheFly – the ultimate source...

11d ago

BIAF

BioAffinity Technologies announces 1-for-30 reverse split

BioAffinity Technologies (BIAF) announced that it will effect a 1-for-30 reverse split of its common stock. Commencing with...

13d ago

BIAF

bioAffinity Technologies Implements Reverse Stock Split

An update from bioAffinity Technologies, Inc. ( ($BIAF) ) is now available. On July 25, 2025, bioAffinity Technologies,...

12d ago

BIAF

bioAffinity Technologies Unveils New CyPath® Lung Case Study

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an update. On September 9, 2025, bioAffinity Technologies announced a...

20d ago

BIAF

bioAffinity Technologies Prepares for H.C. Wainwright Conference

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an update. bioAffinity Technologies, Inc., a Delaware corporation, has prepared...

24d ago

BIAF

bioAffinity Technologies’ CyPath® Lung Test Featured in U.S. Medicine

The latest update is out from bioAffinity Technologies, Inc. ( ($BIAF) ). On September 3, 2025, bioAffinity Technologies...

26d ago

BIAF

bioAffinity Amends Warrant Floor Price in Recent Agreement

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an update. On September 2, 2025, bioAffinity Technologies, Inc. announced...

27d ago

BIAF

BioAffinity Technologies files to sell 12.61M shares of common stock for holders

16:17 EDT BioAffinity Technologies (BIAF) files to sell 12.61M shares of common stock for holders Published first on...

1M ago

BIAF

Hold Rating for bioAffinity Technologies Amid Growth Prospects and Financial Challenges

Maxim Group analyst Anthony Vendetti has maintained their neutral stance on BIAF stock, giving a Hold rating on...

1M ago

BIAF

bioAffinity Technologies Appoints New Board Members

bioAffinity Technologies, Inc. ( ($BIAF) ) has provided an announcement. On August 12, 2025, bioAffinity Technologies appointed Roberto...

1M ago

BIAF

BIAF FAQ

What was bioAffinity Technologies, Inc.’s price range in the past 12 months?

bioAffinity Technologies, Inc. lowest stock price was $3.40 and its highest was $67.11 in the past 12 months.

What is bioAffinity Technologies, Inc.’s market cap?

bioAffinity Technologies, Inc.’s market cap is $7.08M.

When is bioAffinity Technologies, Inc.’s upcoming earnings report date?

bioAffinity Technologies, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 43 days.

How were bioAffinity Technologies, Inc.’s earnings last quarter?

bioAffinity Technologies, Inc. released its earnings results on Aug 14, 2025. The company reported -$5.1 earnings per share for the quarter, missing the consensus estimate of -$3 by -$2.1.

Is bioAffinity Technologies, Inc. overvalued?

According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does bioAffinity Technologies, Inc. pay dividends?

bioAffinity Technologies, Inc. does not currently pay dividends.

What is bioAffinity Technologies, Inc.’s EPS estimate?

bioAffinity Technologies, Inc.’s EPS estimate is -2.7.

How many shares outstanding does bioAffinity Technologies, Inc. have?

bioAffinity Technologies, Inc. has 1,338,029 shares outstanding.

What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?

bioAffinity Technologies, Inc. reported an EPS of -$5.1 in its last earnings report, missing expectations of -$3. Following the earnings report the stock price went down -8.81%.

Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?

Currently, no hedge funds are holding shares in BIAF

Company Description

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

bioAffinity Technologies, Inc. (BIAF) Earnings & Revenues

Historic Earnings Reports

BIAF Stock 12 Month Forecast

Average Price Target

$0.50

▼(-90.55% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"$74","-1":"-$1","17.75":"$17.75","36.5":"$36.5","55.25":"$55.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,17.75,36.5,55.25,74],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.1,6.592307692307692,6.084615384615384,5.576923076923077,5.069230769230769,4.561538461538461,4.053846153846154,3.546153846153846,3.0384615384615383,2.5307692307692307,2.023076923076923,1.5153846153846153,1.0076923076923077,{"y":0.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.1,6.592307692307692,6.084615384615384,5.576923076923077,5.069230769230769,4.561538461538461,4.053846153846154,3.546153846153846,3.0384615384615383,2.5307692307692307,2.023076923076923,1.5153846153846153,1.0076923076923077,{"y":0.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.1,6.592307692307692,6.084615384615384,5.576923076923077,5.069230769230769,4.561538461538461,4.053846153846154,3.546153846153846,3.0384615384615383,2.5307692307692307,2.023076923076923,1.5153846153846153,1.0076923076923077,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.5,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":72,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.6,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.7,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.25,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.88,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >